Takeda Pharmaceutical

TAK

Market cap $51.1B

Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood.

Japan's Takeda Pharmaceutical said on Thursday its experimental pill for a type of skin disease, developed using artificial intelligence, succeeded in two late-stage studies.

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda's Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment.

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide's efficacy and safety and demonstrate du.

SAN FRANCISCO and SUZHOU, China, Dec. 4, 2025 /PRNewswire/ -- Innovent Biologics (HKEX: 01801) today announced that the global strategic collaboration with Takeda (TSE: 4502, NYSE: TAK) has closed and become effective following the satisfaction of all closing conditions. The collaboration, initially announced on October 22, 2025 , aims to accelerate the global development and commercialization of Innovent's next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, including the global partnership on IBI363 (PD-1/IL-2α-bias) and IBI343 (CLDN18.2 ADC), and an option for an early-stage program IBI3001 (EGFR/B7H3 ADC).

The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder drug, the health regulator said on Friday.

BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leading neurotechnology company powering AI-driven neurodiagnostics and precision medicines for the brain, today announced a multi-year expansion of its strategic collaboration with Takeda, which began in 2024. This extension leverages the Beacon Platform to accelerate data-driven development of sleep biomarkers and patterns, and supports new diagnostic pathways that close longstanding care gaps for people with narcolepsy. Under the terms of the agreement, Beacon is eligible to receive up to $109 million in data license fees and potential development, regulatory, and commercial-based milestones, including equity participation.

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin A (IgA) nephropathy. Data from the study showed that kidney function (eGFR) remained stable in patients with IgA nephropathy through Week 96 – up to 18 months after the last mezagitamab dose.1 The result.

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced the completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial evaluating its dengue vaccine, QDENGA®▼(Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). These data, including an exploratory analysis of a booster dose, confirm the favorable benefit and risk profile of QDENGA and that the two-dose regimen provides sustained protection against dengue. Th.